1. Home
  2. >>
  3. LATEST
  4. >>
  5. There are diabetes medications that can delay the progression of Alzheimer’s

There are diabetes medications that can delay the progression of Alzheimer’s



There are diabetes medications that can delay the progression of Alzheimer’s


A new study has found an association between a particular class of drugs used to treat type 2 diabetes and the reduction of Alzheimer’s disease biomarkers. The reason this neuroprotective effect occurs is unknown, but scientists are now calling for large-scale clinical trials to explore these potential treatments in non-diabetic groups.

The researchers noted higher rates of dementia in patients with type 2 diabetes. A study performed earlier this year suggested that hypertension could explain the relationship between diabetes and dementia, but it is not yet clear what links the two conditions. On the other hand, observations of abnormally low rates of neurodegenerative diseases in groups of diabetic patients taking certain antidiabetic drugs have increased.

  The trick that keeps your computer on and convinces your boss you’re working

Another study showed that older patients taking metformin they had a slower cognitive decline compared to people without diabetes who were not taking this drug.

The new study

Now, this new scientific study has looked at a particular class of diabetes drugs called dipeptidyl peptidase 4 (DPP-4i) inhibitors, also known as gliptins. The researchers compared brain CT data and cognitive test results from 70 diabetic patients taking DPP-4i, 71 diabetic patients not taking DPP-4i, and 141 non-diabetic patients. All the participants showed the first signs of the Alzheimer’s disease and they had an average age of 76.

Followed up for about six years, diabetic patients taking DPP-4i had significantly slower rates of cognitive decline than the other groups.

  Klevv announces DDR5 memories with up to 6400 MHz and RGB lighting

Looking at the primary biomarker of Alzheimer’s disease, amyloid protein buildup in the brain, the study found that patients taking DPP-4i had lower average levels than other diabetic and non-diabetic patients.

The results of the study were recently published in the scientific journal Neurology.